A Study of Gastric Delay in Migraine Patients (3207-003)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00548353|
Recruitment Status : Completed
First Posted : October 23, 2007
Last Update Posted : December 19, 2014
|Condition or disease||Intervention/treatment||Phase|
|Migraine Disorders||Drug: MK3207 Drug: Comparator: Placebo (unspecified)||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||22 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||A Randomized, Double-Blind, Placebo Controlled, 2-Period, Fixed-Sequence Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Orally Administered MK3207 in Patients During and Between Their Acute Migraine Attacks|
|Study Start Date :||August 2007|
|Primary Completion Date :||April 2008|
|Study Completion Date :||February 2010|
MK3207 Orally administered to patients with water. During each period (with and without acute migraine).
M3207 (20 mg); patients will be administered a single dose of 100 mg of MK3207 (i.e., 5 x20-mg tablets).
Placebo Comparator: 2
MK3207 placebo as tablets will be Orally administered to patients with water. During each period (with and without acute migraine).
Drug: Comparator: Placebo (unspecified)
M3207 (20 mg) Pbo; patients will be administered a single dose of 100 mg of MK3207 Pbo (i.e., 5 x20-mg tablets).
- Safety in migraine patients [ Time Frame: 12 Weeks ]
- PK in migraine patients [ Time Frame: 12 Weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00548353
|Study Director:||Medical Monitor||Merck Sharp & Dohme Corp.|